Literature DB >> 19076434

Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Chun Zhou1, Yong Huang, Serge Przedborski.   

Abstract

Parkinson's disease (PD) is a common adult-onset neurodegenerative disorder. Typically PD is a sporadic neurological disorder, and over time affected patients see their disability growing and their quality of life declining. Oxidative stress has been hypothesized to be linked to both the initiation and the progression of PD. Preclinical findings from both in vitro and in vivo experimental models of PD suggest that the neurodegenerative process starts with otherwise healthy neurons being hit by some etiological factors, which sets into motion a cascade of deleterious events. In these models initial molecular alterations in degenerating dopaminergic neurons include increased formation of reactive oxygen species, presumably originating from both inside and outside the mitochondria. In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD, time-course experiments suggest that oxidative stress is an early event that may directly kill some of the dopaminergic neurons. In this model it seems that oxidative stress may play a greater role in the demise of dopaminergic neurons indirectly by activating intracellular, cell death-related, molecular pathways. As the neurodegenerative process evolves in the MPTP mouse model, indices of neuroinflammation develop, such as microglial activation. The latter increases the level of oxidative stress to which the neighboring compromised neurons are subjected to, thereby promoting their demise. However, these experimental studies have also shown that oxidative stress is not the sole deleterious factor implicated in the death of dopaminergic neurons. Should a similar multifactorial cascade underlie dopaminergic neuron degeneration in PD, then the optimal therapy for this disease may have to rely on a cocktail of agents, each targeting a different critical component of this hypothesized pathogenic cascade. If correct, this may be a reason why neuroprotective trials using a single agent, such as an antioxidant, have thus far generated disappointing results.

Entities:  

Mesh:

Year:  2008        PMID: 19076434      PMCID: PMC2745097          DOI: 10.1196/annals.1427.023

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  100 in total

1.  Brain dialysis in conscious rats reveals an instantaneous massive release of striatal dopamine in response to MPP+.

Authors:  H Rollema; G Damsma; A S Horn; J B De Vries; B H Westerink
Journal:  Eur J Pharmacol       Date:  1986-07-31       Impact factor: 4.432

2.  Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease.

Authors:  D T Dexter; C J Carter; F R Wells; F Javoy-Agid; Y Agid; A Lees; P Jenner; C D Marsden
Journal:  J Neurochem       Date:  1989-02       Impact factor: 5.372

Review 3.  Brain monoamine oxidase (MAO) B: a unique neurotoxin and neurotransmitter producing enzyme.

Authors:  M B Youdim
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1989       Impact factor: 5.067

4.  Brain peroxidase and catalase in Parkinson disease.

Authors:  L M Ambani; M H Van Woert; S Murphy
Journal:  Arch Neurol       Date:  1975-02

5.  Glutathione peroxidase activity in Parkinson's disease brain.

Authors:  S J Kish; C Morito; O Hornykiewicz
Journal:  Neurosci Lett       Date:  1985-08-05       Impact factor: 3.046

6.  Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease.

Authors:  Makoto Sohmiya; Makoto Tanaka; Nyou Wei Tak; Makoto Yanagisawa; Yutaka Tanino; Yoko Suzuki; Koichi Okamoto; Yorihiro Yamamoto
Journal:  J Neurol Sci       Date:  2004-08-30       Impact factor: 3.181

7.  Iron-sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease.

Authors:  Li-Ping Liang; Manisha Patel
Journal:  J Neurochem       Date:  2004-09       Impact factor: 5.372

8.  A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra.

Authors:  H Saggu; J Cooksey; D Dexter; F R Wells; A Lees; P Jenner; C D Marsden
Journal:  J Neurochem       Date:  1989-09       Impact factor: 5.372

9.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.

Authors:  E Hirsch; A M Graybiel; Y A Agid
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

10.  Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus.

Authors:  R J Marttila; H Lorentz; U K Rinne
Journal:  J Neurol Sci       Date:  1988-09       Impact factor: 3.181

View more
  146 in total

1.  Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.

Authors:  Judith Eschbach; Björn von Einem; Kathrin Müller; Hanna Bayer; Annika Scheffold; Bradley E Morrison; K Lenhard Rudolph; Dietmar R Thal; Anke Witting; Patrick Weydt; Markus Otto; Michael Fauler; Birgit Liss; Pamela J McLean; Albert R La Spada; Albert C Ludolph; Jochen H Weishaupt; Karin M Danzer
Journal:  Ann Neurol       Date:  2014-12-19       Impact factor: 10.422

2.  ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.

Authors:  Mauhamad Baarine; Craig Beeson; Avtar Singh; Inderjit Singh
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

3.  SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease.

Authors:  Pablo Garcia-Reitböck; Oleg Anichtchik; Arianna Bellucci; Mariangela Iovino; Chiara Ballini; Elena Fineberg; Bernardino Ghetti; Laura Della Corte; PierFranco Spano; George K Tofaris; Michel Goedert; Maria Grazia Spillantini
Journal:  Brain       Date:  2010-06-09       Impact factor: 13.501

Review 4.  NADPH oxidases: novel therapeutic targets for neurodegenerative diseases.

Authors:  Hui-Ming Gao; Hui Zhou; Jau-Shyong Hong
Journal:  Trends Pharmacol Sci       Date:  2012-04-11       Impact factor: 14.819

5.  Effects of acute dieldrin exposure on neurotransmitters and global gene transcription in largemouth bass (Micropterus salmoides) hypothalamus.

Authors:  Christopher J Martyniuk; April Feswick; Daniel J Spade; Kevin J Kroll; David S Barber; Nancy D Denslow
Journal:  Neurotoxicology       Date:  2010-05-11       Impact factor: 4.294

6.  A dopamine receptor contributes to paraquat-induced neurotoxicity in Drosophila.

Authors:  Marlène Cassar; Abdul-Raouf Issa; Thomas Riemensperger; Céline Petitgas; Thomas Rival; Hélène Coulom; Magali Iché-Torres; Kyung-An Han; Serge Birman
Journal:  Hum Mol Genet       Date:  2014-08-25       Impact factor: 6.150

7.  Glutathione S-transferase pi mediates MPTP-induced c-Jun N-terminal kinase activation in the nigrostriatal pathway.

Authors:  Margarida Castro-Caldas; Andreia Neves Carvalho; Elsa Rodrigues; Colin Henderson; C Roland Wolf; Maria João Gama
Journal:  Mol Neurobiol       Date:  2012-04-27       Impact factor: 5.590

8.  Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.

Authors:  Chee Yeun Chung; James B Koprich; Penelope J Hallett; Ole Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

Review 9.  Mitochondrial dysfunction in mouse models of Parkinson's disease revealed by transcriptomics and proteomics.

Authors:  Desmond J Smith
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

10.  Parkinson's disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance.

Authors:  Charles R Arthur; Stephanie L Morton; Lisa D Dunham; Paula M Keeney; James P Bennett
Journal:  Mol Neurodegener       Date:  2009-09-23       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.